

## SUPPLEMENTARY INFORMATION

**Title:** All-trans retinoic acid stimulates viral mimicry, interferon responses and antigen presentation in breast-cancer cells

Marco Bolis<sup>1,2</sup>, Gabriela Paroni<sup>1</sup>, Maddalena Fratelli<sup>1</sup>, Arianna Vallergera<sup>1</sup>, Adriana Zanetti<sup>1</sup>, Mami Kurosaki<sup>1</sup>, Silvio Ken Garattini<sup>3</sup>, Maurizio Gianni<sup>1</sup>, Monica Lupi<sup>4</sup>, Linda Pattini<sup>5</sup>, Maria Monica Barzago<sup>1</sup>, Mineko Terao<sup>1</sup> and Enrico Garattini<sup>1</sup>

<sup>1</sup>Laboratory of Molecular Biology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, via La Masa 19, 20156 Milano Italy. <sup>2</sup>Functional Cancer Genomics Laboratory, Institute of Oncology Research; Bioinformatics Core Unit, SIB-Swiss Institute of Bioinformatics; USI, University of Southern Switzerland. Bellinzona, Switzerland. <sup>3</sup>DAME, Dipartimento di Area Medica Università degli Studi di Udine. Department of Oncology, Azienda Ospedaliera di Udine, Udine, Italy. <sup>4</sup>Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, via La Masa 19, 20156 Milano Italy. <sup>5</sup> Department of Electronics, Information and Bioengineering, Politecnico di Milano, Milano

Supplementary Methods	pages 2-4
Legends to Supplementary Tables S1-S4	pages 4-5
Supplementary Figures S1-S15	pages 6-20
Original Western blots of Figures 5-7	pages 21-31

## SUPPLEMENTARY METHODS

*Cell lines:* The table below summarizes the characteristics and the source of the cell lines used throughout the study:

<b>Cell name</b>	<b>Gender</b>	<b>Phenotype</b>	<b>Source</b>
<i>AU565</i>	F	Luminal (HER2 <sup>+</sup> )	ATCC
<i>BT20</i>	F	Basal (TNBC)	ATCC
<i>BT474</i>	F	Luminal (ER <sup>+</sup> /HER2 <sup>+</sup> )	ATCC
<i>BT483</i>	F	Luminal (ER <sup>+</sup> )	ATCC
<i>BT549</i>	F	Basal (TNBC)	ATCC
<i>CAL-120</i>	F	Basal (TNBC)	DSMZ
<i>CAL-148</i>	F	Basal (TNBC)	DSMZ
<i>CAL-51</i>	F	Basal (TNBC)	DSMZ
<i>CAL-851</i>	F	Basal (TNBC)	DSMZ
<i>CAMA1</i>	F	Luminal (ER <sup>+</sup> )	ATCC
<i>DU4475</i>	F	Basal (TNBC)	ATCC
<i>EFM192A</i>	F	Luminal (ER <sup>+</sup> /HER2 <sup>+</sup> )	DSMZ
<i>EFM19</i>	F	Luminal (ER <sup>+</sup> /HER2 <sup>+</sup> )	DSMZ
<i>HCC-1143</i>	F	Basal (TNBC)	ATCC
<i>HCC-1187</i>	F	Basal (TNBC)	ATCC
<i>HCC-1395</i>	F	Basal (TNBC)	ATCC
<i>HCC-1419</i>	F	Luminal (HER2 <sup>+</sup> )	ATCC
<i>HCC-1428</i>	F	Luminal (ER <sup>+</sup> )	ATCC
<i>HCC1500</i>	F	Luminal (ER <sup>+</sup> )	ATCC
<i>HCC-1569</i>	F	Basal (TNBC)	ATCC
<i>HCC-1599</i>	F	Basal (TNBC)	ATCC
<i>HCC-1806</i>	F	Basal (TNBC)	ATCC
<i>HCC-1937</i>	F	Basal (TNBC)	ATCC
<i>HCC-1954</i>	F	Basal (TNBC)	ATCC
<i>HCC-202</i>	F	Luminal (HER2 <sup>+</sup> )	ATCC
<i>HCC-2218</i>	F	Luminal (HER2 <sup>+</sup> )	ATCC
<i>HCC-38</i>	F	Basal (TNBC)	ATCC
<i>HCC-70</i>	F	Basal (TNBC)	ATCC
<i>HDQP1</i>	F	Basal (TNBC)	DSMZ
<i>Hs281T</i>	F	Basal (TNBC)	ATCC
<i>Hs343T</i>	F	Basal (TNBC)	ATCC
<i>Hs578T</i>	F	Basal (TNBC)	ATCC
<i>KPL1</i>	F	Luminal (ER <sup>+</sup> )	DSMZ
<i>MB-157</i>	F	Basal (TNBC)	ATCC
<i>MCF7</i>	F	Luminal (ER <sup>+</sup> )	ATCC
<i>MDA-MB-157</i>	F	Basal (TNBC)	ATCC
<i>MDA-MB-134VI</i>	F	Luminal (ER <sup>+</sup> )	ATCC
<i>MDA-MB-175VII</i>	F	Luminal (ER <sup>+</sup> )	ATCC

<i>MDA-MB-231</i>	F	Basal (TNBC)	ATCC
<i>MDA-MB-361</i>	F	Luminal (ER <sup>+</sup> /HER2 <sup>+</sup> )	ATCC
<i>MDA-MB-415</i>	F	Luminal (ER <sup>+</sup> )	ATCC
<i>MDA-MB-435S</i>	F	Basal (TNBC)	ATCC
<i>MDA-MB-436</i>	F	Basal (TNBC)	ATCC
<i>MDA-MB-453</i>	F	Basal (TNBC)	ATCC
<i>MDA-MB-468</i>	F	Basal (TNBC)	ATCC
<i>SK-BR-3</i>	F	Luminal (HER2 <sup>+</sup> )	ATCC
<i>T47D</i>	F	Luminal (ER <sup>+</sup> )	ATCC
<i>UACC-812</i>	F	Luminal (ER2 <sup>+</sup> /HER2 <sup>+</sup> )	ATCC
<i>ZR75.1</i>	F	Luminal (ER <sup>+</sup> )	ATCC
<i>ZR75.30</i>	F	Luminal (ER <sup>+</sup> /HER2 <sup>+</sup> )	ATCC

ATCC = American Type Culture Collection; DSMZ = Deutsche Sammlung von Mikroorganismen und Zellkulturen; SIGMA = Sigma-Aldrich. The cell-lines marked in yellow are the 16 cell-lines used to perform the RNA-seq experiments following treatment with ATRA.

*Polymerase Chain Reaction experiments:* The expression of the following transcripts was evaluated with the use of commercially available taqman assays according to the instructions of the manufacturer (Applied Biosystems): Dihydroorotate dehydrogenase (DHODH, NM\_001361.4; assay ID-Hs00361406\_m1); Minichromosome maintenance complex component 6 (MCM6, NM\_005915.5; assay ID-Hs00195504\_m1); Minichromosome maintenance complex component 2 (MCM2, NM\_004526.3; assay ID-Hs01091568\_g1); Poly (ADP-ribose) polymerase family, member 14 (PARP14, NM\_017554.2; Hs00393814\_m1).

*Identification of genetic perturbations proportional to ATRA-sensitivity and generation of ATRA-sensitivity associated gene interaction networks:* After a first phase of differential expression analysis, we determined for each gene, the correlation between ATRA-induced fold changes across cell-lines and the respective ATRA sensitivity scores. Subsequently, we filtered out genes with either Pearson's or Spearman's correlation coefficients associated p-values lower than 0.01. We adopted both metrics in order to obtain more inclusive results. We further discarded genes showing a

coefficient of variation across cell-lines being lower than 0.5 and obtained a final list consisting of 754 genes, whose perturbations are associated with ATRA responsiveness. Finally, we constructed a protein-protein interaction network using the *STRING* database and discarded all elements with less than three edges. A scheme of the strategy used for the analysis of the data is available in Supplementary Figure S2.

## LEGENDS TO SUPPLEMENTARY TABLES

### **Supplementary Table S1** *Genes up- and down-regulated by ATRA in breast-cancer cell-lines*

The indicated cell-lines were treated with DMSO or ATRA (1  $\mu$ M) for 24 hours. Whole-genome gene-expression analysis was performed by *RNA-seq*. The table contains the list of 754 genes significantly up- and down-regulated by ATRA and whose ATRA-dependent expression is quantitatively and significantly correlated with the *ATRA-score*. The expression data are shown as the  $\log_2$  of the ATRA/DMSO fold-change and the values calculated derive from 3 biological replicates. The values corresponding to the following correlation indexes are provided:  $p_{\text{RHO}}$  = p-value of the Spearman's correlation between ATRA/DMSO fold-change and *ATRA-score*;  $\text{RHO}$  = Spearman's correlation coefficient between ATRA/DMSO fold-change and *ATRA-score*;  $p_{\text{R}}$  = p-value of the Pearson's correlation between ATRA/DMSO fold-change and *ATRA-score*;  $\text{R}$  = Pearson's correlation coefficient between ATRA/DMSO fold-change and *ATRA-score*;  $\text{CV}$  = Coefficient of variation.

### **Supplementary Table S2** *Enrichment analyses of the gene-sets up- and down-regulated by ATRA which are quantitatively associated with ATRA sensitivity in breast-cancer cell-lines*

Each breast-cancer cell-line was treated with vehicle (DMSO) or ATRA ( $10^{-6}$  M) for 24 hours. Total RNA was extracted and subjected to *RNA-seq* analysis. The gene-sets up- or down-regulated

by ATRA and whose significance is proportional to ATRA-sensitivity were subjected to GSEA (Gene Set Enrichment Analysis) using the HALLMARK and the CURATED datasets. The FDR (False Discovery Rate) values and the ATRA-dependent up-or down-regulation are indicated.


**Supplementary Table S3** *Enrichment analyses of the gene-sets up- and down-regulated by ATRA in HCC-1599 xenografts*

Three separate SCID mice/experimental group were transplanted sub-cutaneously with *HCC-1599* cells. Animals were administered two daily doses of vehicle or ATRA (15 mg/kg) orally. RNA was extracted from the isolated tumor tissues and subjected to microarray gene-expression analysis. The gene-sets up- or down-regulated by ATRA were subjected to GSEA (Gene Set Enrichment Analysis) using the HALLMARK and the CURATED datasets. The FDR values and the ATRA-dependent up-or down-regulation are indicated.

**Supplementary Table S4** *Effect of ATRA on the expression of interferon genes in breast cancer cell-lines*


Each breast-cancer cell-line was treated with vehicle (DMSO) or ATRA ( $10^{-6}$  M) for 24 hours. Total RNA was extracted and subjected to *RNA-seq* analysis. The expression levels of the transcripts encoding the indicated interferon (IFN) species were determined. Each value is the mean of 3 replicate cultures treated with vehicle (DMSO) or ATRA.





**Supplementary Figure S2** *Identification of the genes differentially regulated by ATRA in sensitive cell-lines*


Biological triplicates of 16 breast cancer cell-lines were treated with vehicle (DMSO) or ATRA ( $10^{-6}$  M) for 24 hours. Total RNA was extracted and subjected to *RNA-seq* analysis. The flow-chart illustrates the computational approach applied to define the 754 genes whose expression is significantly perturbed by ATRA and quantitatively correlated with cell-line sensitivity to the anti-proliferative activity of ATRA (*ATRA-score* value).



### Supplementary Figure S3 Validation of the RNA-seq data

The *RNA-seq* data were validated by Taqman analysis of the 4 indicated genes in all the cell-lines considered. The indicated cell-lines were treated with vehicle (DMSO) or ATRA ( $10^{-6}$  M) for 24 hours. Total RNA was extracted and subjected to Taqman analysis using specific oligonucleotide probes targeting the PARP14, MCM2, MCM6 and DHODH mRNAs. Each column represents the Mean  $\pm$  SD of 3 replicate cultures. The scatter plots on the right show the correlation between the Taqman and the *RNA-seq* data in each cell-line exposed to vehicle or ATRA ( $n = 32$ ). The  $r$  value of each correlation is shown. PARP14 = Poly (ADP-ribose) polymerase family, member 14; MCM2 = Minichromosome maintenance complex component 2; MCM6 = Minichromosome maintenance complex component 6; DHODH = dihydroorotate dehydrogenase.






**Supplementary Figure S4** Effects of ATRA on the genes belonging to the “MYC Targets”, “E2F Targets” and “G2M Checkpoint” gene-sets

The indicated cell lines were treated with vehicle (DMSO) or ATRA (1  $\mu$ M) for 24 hours. Total RNA was extracted and subjected to *RNA-seq* analysis. The heat-maps show the effects exerted by ATRA on the expression of the genes belonging to the CURATED “MYC Targets”, “E2F Targets” and “G2M Checkpoint” gene-sets. The data are expressed as the ATRA/DMSO fold change. The “MYC Targets” gene-set is a merged version of the CURATED “MYC Targets V1” and the “MYC Targets V2” gene-sets. Each of the “MYC Targets” “E2F Targets” and “G2M Checkpoint” gene-sets consist of 200 genes and the heat-maps show the 50 top-ranking genes significantly correlated to the ATRA-score of the indicated cell-lines. The cell-lines are ordered according to their ATRA-score from left to right and the ATRA-score values are shown on the top. The cell-lines marked in blue have a basal phenotype, while the cell-lines marked in red are endowed with a luminal phenotype.






**Supplementary Figure S6** Gene-network enrichment analysis of the RNA-seq results obtained in breast-cancer cell-lines


Gene-network enrichment analysis was performed on the 754 genes whose up-or down-regulation is proportional to ATRA-sensitivity, using the CURATED gene-sets. The top 30 down-regulated gene-networks are shown by the blue-column graph on the left, while the top 30 up-regulated gene-networks are illustrated by the red-column graph on the right. The horizontal line indicates the FDR threshold value considered. Gene-sets involved in the control of: Green = proliferation/cell-cycle; Brown = histone/chromatin organization and “Missiaglia-Regulated-by-Methylation-UP”; Orange = Myc-pathway; Grey = estrogen-responses; Violet = interferon/inflammatory responses.






**Supplementary Figure S7** Gene-network enrichment analysis of the RNA-seq results obtained in HCC-1599 xenografts

HCC-1599 cells were transplanted in nude mice subcutaneously. Xenografted animals were treated with vehicle or ATRA according to the scheme illustrated in Centritto *et al.* (EMBO Mol Med 7, 950–972). Twenty four hours following the last treatment, the HCC-1599 xenografts of 3 ATRA-treated and 3 vehicle treated animals were subjected to whole-genome gene-expression microarray analysis. Genes significantly up- and down-regulated by ATRA were subjected to gene-network enrichment analysis using the CURATED gene-sets. The top 30 down-regulated gene-sets are shown by the blue-column graph on the left, while the top 30 up-regulated gene-sets are illustrated by the red-column graph on the right. The horizontal line indicates the FDR (False Discovery Rate) threshold value considered. Orange = genes involved in the Myc-pathway; Blue = genes involved in the metastatic process; Brown = genes involved in the DNA methylation process; Violet = genes involved in interferon responses; Grey = genes involved in the estrogen-receptor pathway.




**Supplementary Figure S8** *Sensitivity of breast cancer cell-lines to the anti-proliferative activity of ATRA*

The column diagram illustrates the experimental *ATRA-score* values calculated for the indicated cell-lines. The 14 cell-lines belonging to our experimental panel are shown in blue (basal cell-lines) and red (luminal cell-lines). The basal or luminal phenotype of all the other cell-lines is indicated by a blue and a red dot, respectively. The dotted red line represents the threshold *ATRA-score* value (0.17) used to separate the cell-lines binomially in two groups characterized by high and low *ATRA*-sensitivity.




**Supplementary Figure S9** *Effects of ATRA on the immunophenograms of luminal cell-lines*

The indicated luminal cell lines were treated with vehicle (DMSO) or ATRA (1  $\mu$ M) for 24 hours. Total RNA was extracted and subjected to *RNA-seq* analysis. The circles show the effects exerted by ATRA on the immunophenograms derived from the *RNA-seq* data. The *ATRA-score* of each cell-line is indicated in parenthesis.



**Supplementary Figure S10** Effects of ATRA on the immunophenograms of basal cell-lines


The indicated basal cell lines were treated with vehicle (DMSO) or ATRA (1  $\mu$ M) for 24 hours. Total RNA was extracted and subjected to *RNA-seq* analysis. The circles show the effects exerted by ATRA on the immunophenograms derived from the *RNA-seq* data. The ATRA-score of each cell-line is indicated in parenthesis.



**Supplementary Figure S11** Effects of ATRA on the surface expression of HLA class I antigens in SK-BR-3 cells


The panel illustrates the FACS (Fluorescence Activated Cell Sorter) analyses of the HLA molecules obtained in retinoid sensitive SK-BR-3 cells exposed to ATRA for the indicated time frames.






### Supplementary Fig. S12 *IRF1* and *DTX3L* correlations

The levels of IRF1 and DTX3L proteins as well as mRNAs were determined in 41 breast-cancer cell-lines profiled for their sensitivity to ATRA with the use of the *ATRA-score*. **(A)** The diagrams show the linear correlation plots of IRF1 and DTX3L proteins with the corresponding mRNAs. **(B)** The diagrams show the linear correlation plots of IRF1 and DTX3L proteins with the *ATRA-score* of each cell-line. **(C)** The diagrams show the linear correlation plots of IRF1 and DTX3L mRNAs with the *ATRA-score* of each cell-line.




**Supplementary Figure S13** *IRF1 and DTX3L mRNA expression in primary mammary tumors*

The levels of IRF1 and DTX3L mRNAs were determined on the basis of the *RNA-seq* data of the normal mammary glands and the primary breast-cancer samples available in the TCGA database. **(A)** The panel shows the mRNA expression levels of IRF1 and DTX3L in the single samples indicated. The p-values were adjusted for the FDR using DESEQ2 analysis pipeline. **(B)** The panel illustrates the correlations between the expression levels of DTX3L and IRF1 mRNAs in breast tumors and the normal mammary gland. The data demonstrate a significant direct correlation between the levels of the two mRNAs.




**Supplementary Figure S14** *Correlations between ATRA-dependent IRF1 mRNA/protein and endogenous retrovirus induction in breast cancer cell-lines*

The upper diagram illustrates the correlation between the ATRA-dependent induction of the IRF1-mRNA shown in and the corresponding retinoid-dependent induction of ENV (Endogenous Retroviruses) RNAs (see Figures 5B and 7A). The lower diagram illustrates the same type of correlation observed between the ATRA-dependent induction of the IRF1-protein and the corresponding retinoid-dependent induction of ENV (Endogenous Retroviruses) RNAs.







**Supplementary Fig. S15** *Effects of IRF1 silencing on AM580-induced growth inhibition in SK-BR-3 cells*


SK-BR-3 cells were transiently transfected with *siIRF1(a)* and *siIRF1(b)*, two siRNAs targeting IRF1, or the scrambled *siNC* control. The indicated cells were treated with the RAR $\alpha$  agonist, AM580 (0.1  $\mu$ M), for 96 hours. Cell growth was evaluated and data were analysed as in (A). Values are the mean  $\pm$  SD of 3 replicate cultures.




**Legend:** Original Western blots contained in **Figure 5D**



**Legend:** Original Western blots contained in **Figure 5D**




**Legend:** Original Western blots contained in **Figure 5E**




**Legend:** Original Western blots contained in **Figure 5E**







**Legend:** Original Western blots contained in **Figure 6**




**Legend:** Original Western blots contained in **Figure 6**




**Legend:** Original Western blots contained in **Figure 7A**




**Legend:** Original Western blots contained in **Figure 7B**



**Legend:** Original Western blots contained in **Figure 7C**



**Legend:** Original Western blots contained in **Figure 7D**



**Legend:** Original Western blots contained in **Figures 7E** and **7F**